Exozymes (EXOZ) risk factors

46 risks, 3 new, 5 dropped, 9 reworded since the prior year. The company faces commercialization, scaling, and regulatory hurdles for its lead nutraceutical product, NCT. Reliance on a single facility, third-party manufacturers, and significant insider ownership continue to pose operational risks. Total grant funding grew to $17,697,378 by the end of 2025.

48 risks. Exozymes is a pre-revenue synthetic biology company facing going concern doubts after incurring net losses of $5,861,335 in 2024.